Researchers from the University of Washington in Seattle released data that indicated a potential for improved survival rates for patients with brain metastases who receive stereotactic radiosurgery (SRS). The study, which compared SRS to whole-brain radiation therapy (WBRT) in 413 patients who were diagnosed with non-small cell lung cancer and with fewer than four brain metastases found that those treated with SRS had an overall survival of nine months compared to 3.9 months for patients treated with WBRT. These findings suggest that improved survival rates could be among the benefits that SRS offers to patients diagnosed with the disease.
Contact us to learn more about stereotactic radiosurgery for primary and metastatic brain tumors. We treat brain tumors using CyberKnife® technology, which delivers pinpoint high-dose radiation to tumors in five or fewer outpatient treatments.
This is not intended as medical advice to replace the expertise and judgment of your health care team. It is intended to help you and your family make informed decisions, together with your doctor.